Anthony
TLS Announces Partnership with HDX for BNCT in South Korea
TAE Life Sciences Sponsored Study Details Results of Proton Boron Fusion Therapy Biological Effectiveness
TAE Life Sciences to Sponsor Industry Expert Theater “New Era in Biologically-Targeted Radiation Therapy” at 2021 ASTRO Annual Meeting
TAE Life Sciences Partners with BEC to Incorporate Specialized Robotic Patient Positioning System in its Alphabeam™ System for High-Precision Boron Neutron Capture Therapy
TAE Life Sciences Announces Installation of First Accelerator-based Neutron Beam System for Biologically Targeted Radiation Therapy at Xiamen Humanity Hospital in China
TAE Life Sciences Identifies Proprietary Drug Candidates to Support Boron Neutron Capture Therapy (BNCT)
New Era in Biologically-targeted Radiation Therapy for Cancer Treatment
Developing targeted drugs for boron neutron capture therapy to treat refractory cancers
TAE Life Sciences is developing a next-generation boron neutron capture therapy for cancer. After recently introducing Alphabeam, a compact and affordable accelerator-based neutron system suitable for hospital settings, the company is now focusing on the development of novel boron drugs with improved tumor selectivity and increased 10B loads.
Have questions about BNCT? Get answers on our new BNCT Forum